Yanina Grant-Huerta is CAO at Atara Biotherapeutics, Inc. (ATRA). They have made 5 open-market trades across 1 company since 2025, most recently 2026-08-14.
CIK 0002064348
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ATRA | 49,636 | $419K |
| IMA | 65,000 | $267K |
| Total | $685K |
Shares reported on the most recent Form 4, priced at the 2026-08-17 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ATRA | SELL | 2026-05-18 | 2026-05-20 | $9.13 | $22K | +6.9% | +13.9% | -10.3% |
| ATRA | SELL | 2026-03-02 | 2026-03-04 | $5.08 | $11K | +9.9% | -8.3% | +87.1% |
| ATRA | SELL | 2025-11-17 | 2025-11-19 | $13.19 | $24K | -12.3% | +23.2% | -67.8% |
| ATRA | SELL | 2025-08-18 | 2025-08-20 | $11.61 | $21K | +6.1% | +3.6% | +15.7% |
| ATRA | SELL | 2025-05-16 | 2025-05-20 | $6.76 | $15K | +17.3% | +16.4% | +68.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.